 AUSTIN, Texas, July 31, 2020 GLOBE NEWSWIRE -- Aspira Womens Health, Inc. Nasdaq: AWH, a bioanalytical-based womens health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.Thursday, August 13th 4:30pm ET Domestic:201-689-8472 International:877-407-4021 Conference ID:13706942 Webcast: About Aspira Womens Health Inc. Aspira Womens Health, Inc. formerly known as, Vermillion Inc., Nasdaq: VRML is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1 plus includes our FDA-cleared products, OVA1 and OVERA to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVANEXTM and EndoCheckTM. Visit our website for more information at Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577 